Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | ABBV-787 |
| Synonyms | |
| Therapy Description |
ABBV-787 is an antibody-drug conjugate (ADC) comprising an antibody targeting CD33 linked to a BET degrader, which potentially inhibits proliferation of CD33-positive tumor cells overexpressing BET (NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| ABBV-787 | ABBV 787|ABBV787 | BET Inhibitor (Pan) 33 CD33 Antibody 17 | ABBV-787 is an antibody-drug conjugate (ADC) comprising an antibody targeting CD33 linked to a BET degrader, which potentially inhibits proliferation of CD33-positive tumor cells overexpressing BET (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06068868 | Phase I | ABBV-787 | Study to Evaluate Adverse Events and Movement of Intravenously (IV) Infused ABBV-787 in Adult Participants With Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) | Terminated | USA | ISR | AUS | 2 |